Kenneth Pages, MD
Psychiatry · Tampa, FLNPI 1568494482
Payments from drug & device makers
Across 630 payments — averaging $434.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$204K
- Alkermes, Inc.$46K
- Otsuka America Pharmaceutical, Inc.$10K
- AbbVie$9K
- Johnson & Johnson$2K
- Axsome Therapeutics, Inc.$560
- plus $3K from 16 others
Across 3 payments — averaging $13,333 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neuronetics, Inc.$40K
What the payments were for
- Consulting fees$10,5704%
- Speaking & faculty fees$191,89570%
- Travel & lodging$48,75318%
- Food & beverage$22,6388%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 341 | $203,902 |
| Alkermes, Inc. | 82 | $45,622 |
| Otsuka America Pharmaceutical, Inc. | 52 | $10,208 |
| AbbVie(2 entities) | 38 | $9,076 |
| Johnson & Johnson | 32 | $1,943 |
| Axsome Therapeutics, Inc. | 7 | $560 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $533 |
| Livanova USA, Inc. | 7 | $468 |
| Teva Pharmaceuticals USA, Inc. | 12 | $379 |
| Sunovion Pharmaceuticals Inc. | 13 | $300 |
| Lundbeck LLC | 10 | $171 |
| Jazz Pharmaceuticals Inc. | 5 | $170 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $148 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $117 |
| Bausch Health US, LLC | 7 | $103 |
| Eisai Inc. | 2 | $32 |
| Validus Pharmaceuticals LLC | 2 | $31 |
| Rhodes Pharmaceuticals L.p. | 2 | $26 |
| Corium, LLC | 1 | $24 |
| Shire North American Group Inc | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Neos Therapeutics, LP | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$176,812
- NEUROSTAR TMS THERAPY SYSTEM$168,718
- ARISTADA INITIO$44,203
- NEUROSTAR TMS THERAPY$31,919
- REXULTI$9,081
- VRAYLAR$8,410
- SPRAVATO$1,541
- CAPLYTA$521
- VNS - Symmetry$396
- ABILIFY MAINTENA$364
- Auvelity$355
- AUSTEDO$244
- ABILIFY ASIMTUFII$244
- LATUDA$125
- SUNOSI$122
How this compares
$273,856 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuvelityDextromethorphan Hbr/Bupropion | 27 | $31,839 |
| VraylarCariprazine Hcl | 16 | $25,433 |
| FanaptIloperidone | 12 | $23,546 |
| Asenapine Maleate | 12 | $2,388 |
| Vilazodone Hcl | 19 | $2,369 |
| Aripiprazole | 21 | $1,194 |
| Armodafinil | 12 | $1,192 |
| Chlorpromazine Hcl | 12 | $904 |
| Duloxetine Hcl | 49 | $836 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 17 | $758 |
| Alprazolam | 92 | $758 |
| Temazepam | 25 | $660 |
| Lamotrigine | 42 | $645 |
| Clozapine | 12 | $622 |
| Bupropion XlBupropion Hcl | 43 | $598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Axsome Therapeutics, Inc.Auvelity | $560 | $31,83927 claims |
| AbbVieVraylar | $9,076 | $25,43316 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $15 | $23,54612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Tampa
- Kelley WilsonTampa$11.1M
- Jamie FernandezTampa$2.9M
- Jean FilsTampa$1.1M
- Daniel FallonTampa$724K
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.